Alexandra Drakaki, MD

home / authors / alexandra-drakaki-md

Articles

Alexandra Drakaki, MD, PhD

Dr Drakaki on Nivolumab/Ipilimumab in Advanced RCC With Sarcomatoid Differentiation

Alexandra Drakaki, MD
September 27th 2024

Alexandra Drakaki, MD, PhD, discusses nivolumab plus ipilimumab in the treatment of renal cell carcinoma with sarcomatoid differentiation.

Read More

Alexandra Drakaki, MD, PhD

Dr Drakaki on a Case Study in ALK+ Refractory Metastatic RCC

Alexandra Drakaki, MD
September 24th 2024

Alexandra Drakaki, MD, PhD, discusses a case study of a patient with refractory metastatic renal cell carcinoma harboring an ALK rearrangement.

Read More

Alexandra Drakaki, MD, PhD

Dr Drakaki on Paradigm-Shifting Trials in Non–Clear Cell RCC

Alexandra Drakaki, MD
September 19th 2024

Alexandra Drakaki, MD, PhD, discusses key trials that have shaped the treatment paradigm in non–clear cell renal cell carcinoma.

Read More

Alexandra Drakaki, MD, PhD

Dr Drakaki on the Evolution of Non–Clear Cell RCC Subtype Classifications

Alexandra Drakaki, MD
September 18th 2024

Alexandra Drakaki, MD, PhD, discusses how the classification of subtypes of non–clear cell renal cell carcinoma has evolved in recent years.

Read More

Alexandra Drakaki, MD, PhD

Dr Drakaki on the Investigation of Zanzalintinib in Advanced Non–Clear Cell RCC

Alexandra Drakaki, MD
September 10th 2024

Alexandra Drakaki, MD, PhD, discusses the potential role of zanzalintinib in advanced non–clear cell renal cell carcinoma.

Read More

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

Dr. Drakaki on the Design of the MORPHEUS-mUC Trial in Urothelial Carcinoma

Alexandra Drakaki, MD
March 25th 2020

Alexandra Drakaki, MD, discusses the design of the MORPHEUS-mUC trial in advanced/metastatic urothelial carcinoma.

Read More

Latest Updated Articles

Phase 1/2 ALKOVE-1 study of NVL-655 in ALK-positive (ALK+) solid tumors
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Phase 1 trial of DLL3/CD3 IgG-Like T-Cell Engager BI 764532 in Patients with DLL3 Positive Tumors: Patients with LCNEC
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
Real world evidence of treatment practices and therapeutic outcomes for newly diagnosed NSCLC patients with non-classical EGFR mutations demonstrates high unmet medical need
Published: September 27th 2024 | Updated: October 4th 2024
Real World Evidence of Treatment Practices and Therapeutic Outcomes for Newly Diagnosed NSCLC Patients With Non-Classical EGFR Mutations Demonstrates High Unmet Medical Need